EXEL is expected to report earnings to fall 2.31% to 88 cents per share on November 03
Q3'26
Est.
$0.89
Q2'26
Beat
by $0.07
Q1'26
Beat
by $0.10
Q4'25
Beat
by $0.17
Q3'25
Beat
by $0.09
The last earnings report on August 05 showed earnings per share of 91 cents, beating the estimate of 83 cents. With 982.84K shares outstanding, the current market capitalization sits at 14.62B.
A.I. Advisor
published General Information
General Information
a developer of small molecule therapies for the treatment of cancer
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
EXEL in upward trend: price rose above 50-day moving average on August 31, 2026
EXEL moved above its 50-day moving average on August 31, 2026 date and that indicates a change from a downward trend to an upward trend. In of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 20, 2026. You may want to consider a long position or call options on EXEL as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on August 20, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for EXEL crossed bullishly above the 50-day moving average on August 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EXEL broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EXEL entered a downward trend on August 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.930) is normal, around the industry mean (20.539). P/E Ratio (18.557) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (444.187).
